Cerebrovascular Reactivity in American Football Players

Summary

Investigators will measure cerebrovascular reactivity (CVR) using functional near-infrared spectroscopy (fNIRS) and magnetic resonance imaging (MRI) during the chronic phase after repetitive mild traumatic brain injury (rmTBI) as a biomarker of traumatic cerebrovascular injury (TCVI). We hypothesize that CVR will be decreased in patients with rmTBI and that these decreases will correlate with clinical outcomes. Furthermore, we predict that 5 week administration of a phosphodiesterase 5 (PDE5) inhibitor, sildenafil citrate, will augment CVR in patients with a history rmTBI.

Timeline

Start

2018-03-01

Primary completion

2022-06-30

Completion

2022-06-30

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty enrolling participants due to COVID emergency, and planned start of new study to address this question in a more rigorous fashion.”

Drugs

Indications